Sphingosine 1 Phosphate Receptor Modulators

Agents that affect the function of G-protein coupled SPHINGOSINE 1-PHOSPHATE RECEPTORS. Their binding to the receptors blocks lymphocyte migration and are often used as IMMUNOSUPPRESSANTS.

Also Known As:

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Aguado, J M: 1 article (06/2018)
2.	Cervera, C: 1 article (06/2018)
3.	Fernández-Ruiz, M: 1 article (06/2018)
4.	Manuel, O: 1 article (06/2018)
5.	Michielin, O: 1 article (06/2018)
6.	Redelman-Sidi, G: 1 article (06/2018)
7.	Ribi, C: 1 article (06/2018)
8.	Coskun, Mehmet: 1 article (01/2017)
9.	Nielsen, Ole Haagen: 1 article (01/2017)
10.	Vermeire, Severine: 1 article (01/2017)

Related Diseases

1.	Crohn Disease (Crohn's Disease) 08/01/2022 - "Several new drug classes (Janus kinase inhibitors, anti-integrins, sphingosine-1-phosphate receptor modulators, anti-interleukin-23 antibodies, and stem cell therapies) are currently being studied in Crohn's disease and ulcerative colitis with promising results. "
2.	Ulcerative Colitis 08/01/2022 - "Several new drug classes (Janus kinase inhibitors, anti-integrins, sphingosine-1-phosphate receptor modulators, anti-interleukin-23 antibodies, and stem cell therapies) are currently being studied in Crohn's disease and ulcerative colitis with promising results. "
3.	Infections 10/01/2022 - "Between 6/01/2021 and 11/11/2021, 370 MS patients were recruited (mean age 40.6 years; 76% female; 53% non-White; 22% with prior infection; common DMT classes: ocrelizumab 40%; natalizumab 15%, sphingosine-1-phosphate receptor modulators 13%; and no DMT 8%). " 06/01/2018 - "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)."
4.	Communicable Diseases (Infectious Diseases) 06/01/2018 - "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)."
5.	Inflammation (Inflammations) 01/01/2017 - "In this review we highlight emerging novel and easily administered therapeutics that may be viable candidates for the management of IBD, such as antibodies against interleukin 6 (IL-6) and IL-12/23, small molecules including Janus kinase inhibitors, antisense oligonucleotide against SMAD7 mRNA, and inhibitors of leukocyte trafficking to intestinal sites of inflammation (e.g., sphingosine 1-phosphate receptor modulators). "

Related Drugs and Biologics

1.	Antibodies
2.	Janus Kinase Inhibitors
3.	Interleukin-23 (Interleukin 23)
4.	Integrins
5.	Proteasome Inhibitors
6.	Immune Checkpoint Inhibitors
7.	Interleukin-12 (IL 12)
8.	Antisense Oligonucleotides
9.	Interleukin-6 (Interleukin 6)
10.	Messenger RNA (mRNA)

Related Therapies and Procedures

1.	Therapeutics
2.	Biological Therapy